184 related articles for article (PubMed ID: 11139311)
1. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
Malingré MM; Beijnen JH; Rosing H; Koopman FJ; Jewell RC; Paul EM; Ten Bokkel Huinink WW; Schellens JH
Br J Cancer; 2001 Jan; 84(1):42-7. PubMed ID: 11139311
[TBL] [Abstract][Full Text] [Related]
2. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
Bardelmeijer HA; Beijnen JH; Brouwer KR; Rosing H; Nooijen WJ; Schellens JH; van Tellingen O
Clin Cancer Res; 2000 Nov; 6(11):4416-21. PubMed ID: 11106262
[TBL] [Abstract][Full Text] [Related]
3. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
Veltkamp SA; Alderden-Los C; Sharma A; Rosing H; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2007 Jan; 59(1):43-50. PubMed ID: 16680462
[TBL] [Abstract][Full Text] [Related]
4. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Meerum Terwogt JM; Malingré MM; Beijnen JH; ten Bokkel Huinink WW; Rosing H; Koopman FJ; van Tellingen O; Swart M; Schellens JH
Clin Cancer Res; 1999 Nov; 5(11):3379-84. PubMed ID: 10589748
[TBL] [Abstract][Full Text] [Related]
5. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
[TBL] [Abstract][Full Text] [Related]
6. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
Malingré MM; Beijnen JH; Rosing H; Koopman FJ; van Tellingen O; Duchin K; Ten Bokkel Huinink WW; Swart M; Lieverst J; Schellens JH
Cancer Chemother Pharmacol; 2001 Apr; 47(4):347-54. PubMed ID: 11345652
[TBL] [Abstract][Full Text] [Related]
7. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Kruijtzer CM; Beijnen JH; Rosing H; ten Bokkel Huinink WW; Schot M; Jewell RC; Paul EM; Schellens JH
J Clin Oncol; 2002 Jul; 20(13):2943-50. PubMed ID: 12089223
[TBL] [Abstract][Full Text] [Related]
8. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.
Fidias P; Supko JG; Martins R; Boral A; Carey R; Grossbard M; Shapiro G; Ostler P; Lucca J; Johnson BE; Skarin A; Lynch TJ
Clin Cancer Res; 2001 Dec; 7(12):3942-9. PubMed ID: 11751486
[TBL] [Abstract][Full Text] [Related]
10. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
[TBL] [Abstract][Full Text] [Related]
11. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
12. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats.
Park JH; Park JH; Hur HJ; Woo JS; Lee HJ
Eur J Pharm Sci; 2012 Feb; 45(3):296-301. PubMed ID: 22172604
[TBL] [Abstract][Full Text] [Related]
13. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K
Clin Cancer Res; 2005 Jul; 11(13):4843-50. PubMed ID: 16000582
[TBL] [Abstract][Full Text] [Related]
14. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.
van Asperen J; van Tellingen O; van der Valk MA; Rozenhart M; Beijnen JH
Clin Cancer Res; 1998 Oct; 4(10):2293-7. PubMed ID: 9796957
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats.
Jin J; Bi H; Hu J; Zhong G; Zhao L; Huang Z; Huang M
Biopharm Drug Dispos; 2010 May; 31(4):264-8. PubMed ID: 20437465
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Morrissey LH; Scullin DC; Houston GA; Prasthofer EF; Gray JR; Burris HA; Greco FA
Cancer; 2002 May; 94(9):2426-33. PubMed ID: 12033195
[TBL] [Abstract][Full Text] [Related]
18. Effect of interleukin-2 pretreatment on paclitaxel absorption and tissue disposition after oral and intravenous administration in mice.
Hosten B; Abbara C; Petit B; Dauvin A; Bourasset F; Farinotti R; Gonin P; Bonhomme-Faivre L
Drug Metab Dispos; 2008 Aug; 36(8):1729-35. PubMed ID: 18508881
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2.
Jamois C; Comets E; Mentré F; Marion S; Farinotti R; Bonhomme-Faivre L
Cancer Chemother Pharmacol; 2005 Jan; 55(1):61-71. PubMed ID: 15378273
[TBL] [Abstract][Full Text] [Related]
20. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
